October is PMR Month
Oct 01, 2023
Recent News
Read ArticleYou'll notice this month that RheumNow is dedicating a significant effort and educational space to the topic of polymyalgia rheumatica (PMR) during October 2023
A new download!
ALL the TNR Survey Slides - Hard Decisions in #RA '
https://t.co/mMhxq8VqZY https://t.co/XX1KwTJ6Xh
Oct 01, 2023
Uncertainty on Pre-Clinical #RA – Rheumatologist Survey Results
In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice.
https://t.co/P8d9GbPGoX https://t.co/z4mPvYP6EP
Oct 01, 2023
FDA has approved palovarotene (Sohonos) as 1st Rx for fibrodysplasia ossifcans progressiva (FOP), a severely disabling condition that causes abnormal bone formation in place of soft and connective tissues. https://t.co/s74T0F6Iav https://t.co/Lq6KVXXd0S https://t.co/WabcTQseMa
Oct 01, 2023
Microvascular CV Disease with Severe Psoriasis
While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis.
https://t.co/rUPXR9npRh https://t.co/IuFKj8c7HO
Oct 01, 2023
An observational multicentre study of 51 #EGPA pts treated with dupilumab, which be effective in treating EGPA-related ENT Sxs. EGPA flares occurred in one-third of patients and were preceded by eosinophilia in 88%, - caution is required. https://t.co/YWBp0PtRhC https://t.co/EW6JIK2ib8
Sep 30, 2023
JAKi Safety and Efficacy in bDMARD-IR Patients with RA
View 5-year long-term extension outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/eCWe1Ke8XO https://t.co/gVuH2OkORy
Sep 30, 2023
Cognitive-behavioral Therapy Lessens Fibromyalgia Pain
In a recent clinical trial of patients with fibromyalgia, CBT, was superior to a matched education treatment in reducing the interfering effects of pain and other aspects of fibromyalgia daily.
https://t.co/4wyVEB0SFh https://t.co/Uvu4AzRN4I
Sep 30, 2023
Multicentre retrospective study of 92 pts with paraneoplastic arthritis (PA), found PA seen more w/ hematological malignancies (lymphomas 26%) and solid malignancy (most were lung CA 41.5%). PA pts more likely to be CCP+ (P=0.014). https://t.co/qjs1S4BS3f https://t.co/OgChSl8r7J
Sep 30, 2023
RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)
Sep 29, 2023
This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?
Read Article
A QD Clinic: #RA - GI Fast Track
Seronegative RA with GI Complaints - who should manage this patient?
RA QD Clinics are video vignettes with lessons from the clinic. RA QD Clinics and the "Hard Decisions in RA" September Campaign is sponsored by BMS.
https://t.co/t5s3diKGYK https://t.co/bhdCgNpBw2
Sep 29, 2023
A new download!
ALL the TNR Survey Slides - Hard Decisions in #RA '
https://t.co/cjLigji9I5 https://t.co/itElAVu9ng
Sep 29, 2023
Focus on the Fasting Lipid Profile
There has been much discussion of late regarding the important topic of how best to manage the independent cardiovascular risk associated with rheumatoid arthritis and other rheumatic diseases. #RA
https://t.co/6Ed4vLMj5d https://t.co/oRRvnIWmuZ
Sep 29, 2023
This Tuesday Night Rheumatology panel discusses "DMARD Choices & Changes", including weaning, biosimilars, and guideline views from a panel that includes Drs. Madelaine Feldman, Alan Matsumoto, Artie Kavanaugh and Jack Cush. #RA
https://t.co/zqe0kOM62X https://t.co/lvfNtANx15
Sep 29, 2023
Uncertainty on Pre-Clinical #RA – Rheumatologist Survey Results
In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice.
https://t.co/khPJMuItDB https://t.co/qhtQ8mAKOI
Sep 29, 2023
PBMC RNA-seq studies of Still's pts finds those with #MAS express type I interferon (IFN-I) genes w/ expected IFN-γ signal, coming from cycling CD38+HLA-DR+ cells within CD4+ T cell, CD8+ T cell and NK cell populations. (Synergy w/ IL-15?) https://t.co/QloprexevT https://t.co/JZH2lzZ8rs
Sep 29, 2023
Study of 138 #AOSD (Stills) pts - 19% were obese BMI>30. Obese with AOSD have same clinical features as others, but may have higher ferritin & CRP (correl w/ BMI) and more likely to have chronic disease course and bDMARD failure. https://t.co/16wKVGTWnN https://t.co/daR9hZpA89
Sep 29, 2023
The Future of #RA
Dr. Iain McInnes, Glasgow and Dr. Gerd Burmester, Berlin, discuss their perspectives on the future management of people with rheumatoid arthritis, as part of RheumNow's Hard Decisions in RA campaign.
https://t.co/Lkc7bm8SNy https://t.co/RZUylzlEna
Sep 29, 2023
Rheumatology Advocates Push for Patient Access to Care
ACR
Sep 28, 2023
Physician members of the American College of Rheumatology (ACR), care team members of the Association of Rheumatology Professionals (ARP), and patients living with rheumatic diseases convened on Capitol Hill this week for the annual Advocates for Arthritis conference and to support legislative solutions to issues impacting patient access to care.
Read Article
FDA has approved palovarotene (Sohonos) as 1st Rx for fibrodysplasia ossifcans progressiva (FOP), a severely disabling condition that causes abnormal bone formation in place of soft and connective tissues. https://t.co/oiPMIDzqYP https://t.co/7rfozgPM9I https://t.co/V2w1X137Xa
Sep 28, 2023
Painful Truth of #Gout - affects 2–4% adults in USA, UK, & Europe; >10% Asia-Pacific pts. The global burden of gout is increasing.
- Majority of pts not on ULT
- Majority not T2T monitored
- health literacy on gout is vital https://t.co/ypomR2hhFX https://t.co/JPLLUPJkOE
Sep 28, 2023
From the blog
Dr. Michael Putman (Milwaukee, WI) reviews his approach to screening for ILD and RA, the potential for overdiagnosis and how this impacts treatment choices. Does this differ from your approach?
Read Article
How best do we communicate CV risk associated with RA to other members of the treating team, most particularly the primary care physicians (known as ‘General Practitioners’ here in Australia)? After some experimentation, I have come up with an approach that seems to work and which does not take up much time.
Read Post
Patients with RA have on average two additional other clinical conditions and research shows that these accumulate over time and with longer disease duration. The presence of comorbidities naturally complicates treatment choice, patient adherence to medication and patient outcomes, increasing also the risk of making RA ‘difficult-to-treat’.
Read Post
Podcasts
RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)Sep 29, 2023
RA QD Clinics - Week 4Sep 29, 2023
DMARD Choices & ChangesSep 27, 2023-
RheumNow Podcast – with Special Guest Dr. Michael Weinblatt (9.22.2023)Sep 22, 2023
Therapeutic Updates
Diagnosis of PMR
RheumNow
Oct 01, 2023
Five perspectives now available in the Diagnosis of PMR Therapeutic Update: Importance of Diagnostic Imaging; Which PMR Patients Should Rheumatologists See?; PMR Mimics; PMR: Is There Hidden GCA?; and ESR/CRP in PMR.
Read Post
Poster Hall
